Dutch NK-cell specialist Kiadis Pharma has received $9.5 million in funding for K-NK-ID101, via the Advanced Regenerative Manufacturing Institute’s (ARMI) BioFabUSA program. 15 September 2020
Clinical trials for the AstraZeneca and Oxford University COVID-19 vaccine, AZD1222, have resumed in the UK, following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so, the UK drug major announced today. 12 September 2020
Merck KGaA’s US biotech arm MilliporeSigma has announced a $65 million expansion of its high-potent active pharmaceutical ingredient (HPAPI) and antibody-drug conjugate (ADC) manufacturing capabilities at its Wisconsin, USA-based facility. 11 September 2020
Shares of China-based biotech BeiGene are included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, effective today (September 7), and traded up 3% to HK$146.20 by late afternoon. 7 September 2020
A number of leadership changes at Belgian biotech firm Promethera Biosciences are underway, after key members of the management team resigned from their positions. 2 September 2020
AstraZeneca’s Imfinzi (durvalumab) has been approved in the European Union for the 1st-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC) in combination with a choice of chemotherapies, etoposide plus either carboplatin or cisplatin. 1 September 2020
Ionis Pharmaceuticals has agreed to buy all outstanding shares of Akcea Therapeutics, approximately 24%, for $18.15 per share in cash. 1 September 2020
In the latest update on countries negotiating with pharma over access to unapproved COVID-19 vaccines, Japan is said to be talking to Moderna over acquiring 40 million doses of its mRNA candidate. 28 August 2020
Californian genome engineering firm Synthego has raised $100 million in a series D financing led by new investor Wellington Management, bringing total private funding to more than $250 million. 28 August 2020
Beximco Pharmaceuticals is to collaborate with the Serum Institute of India to become the exclusive supplier of AstraZeneca’s COVID-19 vaccine in Bangladesh, should the product be approved. 28 August 2020
Hong Kong-based Jacobson Pharma has signed a letter of intent with a subsidiary of Shanghai Fosun Pharmaceutical to market and supply up to 10 million doses of BioNTech’s BNT162 mRNA-based vaccine. 27 August 2020
Dutch gene therapy company uniQure today announced the appointment of Ricardo Dolmetsch, as president, research and development, effective September 14, 2020. 25 August 2020
German’s Merck KGaA says that the US Food and Drug Administration has accepted and granted Priority Review to the new drug application (NDA) for once-daily, orally-dosed tepotinib for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC). 25 August 2020
Despite today announcing that the first volunteers have been enrolled in the Phase II portion of its ongoing clinical trial in the USA and Australia to evaluate the immunogenicity and safety of its COVID-19 vaccine candidate, US clinical-stage biotech Novavax’ shares were down more than 14% at $117.87 by late-morning trading. 24 August 2020
Privately-held Harbour BioMed and its and its partners Utrecht University and Erasmus Medical Center have announced a new research collaboration with Viroclinics-DDL and Kiadis Pharma. 19 August 2020
Australia's Prime Minister Scott Morrison said on Tuesday said that the country has signed a deal with AstraZeneca to secure a potential COVID-19 vaccine, joining a growing list of countries lining up supplies of the drug, as reported London South East. 19 August 2020
Swedish Orphan Biovitrum (also known as Sobi) announced today that Ravi Rao has been appointed head of research and development (R&D), as Milan Zdravkovic leaves for new opportunities outside the company. 18 August 2020
Health Canada has approved a new indication for Sanofi and Regeneron’s Dupixent (dupilumab injection), as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP). 18 August 2020
Debiopharm has announced the release of compelling follow-up results from the Phase II study of Debio 1143 alongside chemo-radiation therapy (CRT) versus CRT alone in high-risk patients with locally advanced squamous cell carcinoma of the head and neck. 13 August 2020
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Privately-held Ferring Pharmaceuticals has announced the opening of a global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin (nadofaragene firadenovec-vncg). 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
The BioIndustry Association (BIA), in collaboration with the Centre for Process Innovation (CPI), has published a new report on the UK’s mRNA sector. 2 October 2024
Aspen Neuroscience, a private biotechnology company specializing in autologous cell therapies, has announced the opening of a major new facility near its headquarters in San Diego. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024